Congress tradeDisclosed 4 days after the transaction; reported as an official range, not an exact amount.
Loading…
AbbVie
ABBV · NYSE · Pharmaceuticals
ABBV · NYSE · Pharmaceuticals
Medicines including Humira and Skyrizi.
Last close, Oct 1, 2026
$259.93
Adjusted for splits and dividends
Last 12 months
+6.4%
S&P 500 +14.3% over the same dates
Market value
$459B
Last close × shares outstanding
Bets against the stock: 19.5M shares sold short (1.1% of shares outstanding), -0.1% vs the previous count, 4.5 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
1 sale
$8.18M sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$61.2B
+8.6% vs the year before
Net income, fiscal 2025
$4.23B
As reported in the annual filing
Shares outstanding
1.77B
As of Jul 27, 2026
In fiscal 2025 the company spent $980M buying back its own shares and $11.7B on dividends. Cash actually paid, from its cash-flow statement.
Disclosed 4 days after the transaction; reported as an official range, not an exact amount.
Stock since the trade +4.2% · S&P 500 -1.6% · to Oct 1Traded 14 days after resultsStock 26% above its 52-week low and 5% below its high
107K → 74K shares held−31% of their stake
AbbVie's CHIEF BUS/STRAT OFFICER sold $8.18M of AbbVie shares. Nobody planned it ahead of time.
Officer plans to sell ~$8.18M of AbbVie
Planned, from payFrom a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
2 different filers disclosed ABBV within 90 days. Disclosed 116 days after the transaction; reported as an official range, not an exact amount.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Short sale volume: 53.5% of the volume reported to FINRA over the last 20 trading days was marked short, above its 1-year average of 46.3%. FINRA daily files, to Oct 2, 2026.
Fails to deliver: 16K shares (about $4.02M) were not delivered on time for settlement on Sep 10, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.
Determination That CARAFATE (Sucralfate) Oral Suspension, 1 Gram/10 Milliliters, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Notice · Food and Drug Administration
Determination That NAMENDA (Memantine Hydrochloride) Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Notice · Food and Drug Administration
Certain Antibody Drug Conjugates and Components Thereof and Products Containing the Same; Notice of a Commission Determination Not To Review an Initial Determination Terminating the Investigation; Termination of Investigation
Notice · International Trade Commission
Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
Notice · Food and Drug Administration
Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
Notice · Food and Drug Administration
Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Notice · Food and Drug Administration
Determination That Protamine Sulfate (Protamine Sulfate) Intravenous; Solution, 50 Milligrams/5 Milliliters, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Notice · Food and Drug Administration
Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications
Notice · Food and Drug Administration
Federal rules, proposed rules and notices that name the company by its legal name, from the Federal Register. Being named is not the same as being the target of a rule.
Last 12 months, adjusted daily closes
Adjusted close went from $244.38 on Oct 1, 2025 to $259.93 on Oct 1, 2026 (+6.4%). Disclosed trades in the last 12 months: 0 insider purchases, 6 insider sales, 2 Congress purchases, 7 Congress sales.
15 approvals or clearances and 1 recall recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
Anyone owning more than 5% must file within days. Structured filings exist since December 2024, so older stakes that were never amended may be missing.
4 notices filed with state agencies, covering 144 workers in total. Employers must warn the state ahead of a plant closing or mass layoff at a site.
Official WARN lists from California, Texas, New York, Florida, Illinois and Washington only; notices filed in other states are not shown. Matched on the employer name as filed, so a notice filed under an unrelated subsidiary name can be missing. Dates are the notice date (Washington: the date the state received it).
88 certified in FY2026 Q3, vs 86 a year earlier. 88 positions in total, median offered wage $139K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.